Compugen's Upcoming Q4 and Full Year 2024 Financial Results Insights
Compugen to Announce Financial Results for Q4 and Full Year 2024
Compugen Ltd. (NASDAQ: CGEN), a pioneering clinical-stage company in cancer immunotherapy and computational target discovery, is set to announce its financial results for the fourth quarter and the entire year of 2024. This event will occur before the U.S. markets open on March 4, 2025.
Details of the Conference Call
The management team will hold a conference call and webcast on the same day at 8:30 AM ET, where they will discuss the financial results and share updates on corporate developments. Investors and interested parties can participate by dialing 1-866-744-5399 within the U.S., or +972-3-918-0644 from overseas to join the call.
Accessing the Live Webcast
For those who prefer online streaming, the conference call will be accessible via live webcast through Compugen's official website. Attendees are encouraged to tune in to gain insights into the company’s performance and strategic direction.
About Compugen's Innovative Therapeutics
Compugen’s commitment to innovation is reflected in its robust therapeutics pipeline. Utilizing its advanced predictive computational platform, Unigen™, the company focuses on discovering new drug targets and biological pathways crucial for oncology therapeutics. Among its promising candidates, COM701 is an anti-PVRIG antibody that holds potential as a first-in-class treatment, while COM902 targets TIGIT, positioned as a best-in-class option for patients.
Phase Development and Collaboration
Rilvegostomig, a bispecific antibody, is currently in Phase 3 trials by AstraZeneca, under a licensing agreement aiming to enhance treatment efficacy through combined targeting. Another notable candidate, GS-0321, designed as an anti-IL-18 binding protein, is undergoing Phase 1 trials and is licensed to Gilead, showcasing the breadth of Compugen's collaborative efforts in advancing cancer therapies.
Ongoing Research and Development
Compugen's early-stage immuno-oncology program addresses various mechanisms that aid immune resistance, a critical area of research in cancer treatment. Their well-rounded approach combines innovative science with clinical insight, setting a high bar in the therapeutic landscape.
Commitment to Innovation and Growth
The company is headquartered in Israel with an office presence in San Francisco, California. Compugen not only leads in cancer immunotherapy development but also ensures accessibility for investors by offering clear updates on its growth and projects.
Company Contact Information
For more information, Yvonne Naughton, Ph.D., serves as the VP and Head of Investor Relations and Corporate Communications. Interested parties can reach her via phone at +1 (628) 241-0071.
Frequently Asked Questions
What financial results is Compugen expected to announce?
Compugen will disclose its financial outcomes for the fourth quarter and the entire year of 2024, highlighting key metrics and achievements.
When will the conference call take place?
The conference call is scheduled for March 4, 2025, at 8:30 AM ET, right before the market opens.
How can I listen to the financial results announcement?
Participants can join the call via telephone or access the live webcast on Compugen's official website.
Which key products are included in Compugen's pipeline?
Compugen is developing several candidates, including COM701 and COM902, targeting significant pathways for cancer treatment.
Who can I contact for more information about Compugen?
You can contact Yvonne Naughton, who oversees Investor Relations and Corporate Communications, for further inquiries.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.